CD19 and neoplasm: The addition of plamotamab might offer a potential improved efficacy through the recruitment of distinct T-cell and Fc-mediated cytotoxic mechanisms, while also overcoming tumor resistance that might otherwise arise from the single antigenic loss of either CD19 or CD20.